posted on 2017-04-20, 00:23authored byAnh Thi Ngoc Nguyen
The adenosine A<sub>1</sub> G
protein-coupled receptor (A<sub>1</sub>AR) is an attractive therapeutic target for a range
of cardiovascular and neuronal disorders. However, like many G protein-coupled
receptors (GPCR), the A<sub>1</sub>AR remains sub-optimally targeted due to the lack of
highly subtype-selective agonists and allosteric modulators – despite the fact
that this is the first GPCR for which synthetic small molecule allosteric
enhancers were discovered over two decades ago. Recent development of bitopic
ligands that engage with both the orthosteric site and an allosteric site can
offer considerable potential for greater receptor selectivity, greater affinity
and promote unique receptor conformations that engender biased agonism. To aid
the rational design of more efficacious A<sub>1</sub>AR therapeutics, the focus of this
thesis is to gain greater structural knowledge of the orthosteric, allosteric sites
as well as the mechanisms by which bitopic ligands engage both sites of the
A<sub>1</sub>AR and to develop an VLS approach to identify novel A<sub>1</sub>AR allosteric
modulators. In particular, Chapter 2 and 3 combined alanine scanning
mutagenesis of the A<sub>1</sub>AR-ECL2 with quantitative analytical pharmacology,
homology modeling and molecular dynamics simulations to explore the role of
this domain on the key underlying molecular properties governing A<sub>1</sub>AR
orthosteric and allosteric ligand drug actions, namely, affinity, efficacy and
cooperativity. With the recent appreciation of VLS as a more direct and
rational drug discovery approach to screen large libraries of chemical
structures compared with the traditional experimental HTS, Chapter 4 developed
an approach to optimize the allosteric pocket which can be used to future
large-scale VLS of commercially available compounds to identify novel scaffolds
for A<sub>1</sub>AR allosteric modulators in the absence of an A<sub>1</sub>AR crystal structure. A
novel A<sub>1</sub>AR bitopic ligand, VCP746, was reported to have a biased agonist
profile relative to a number of adenosine-like prototypical A<sub>1</sub>AR agonists and
promoted A<sub>1</sub>AR-mediated cardioprotection in the absence of effects on atrial
heart rate at the A<sub>1</sub>AR. Chapter 5 provides insight into the molecular
determinants involved in the affinity and engagement of signaling of this
bitopic ligand.